OBJECTIVE Since 2010, several non-vitamin K antagonist oral anticoagulants (NOACs) have been brought to the U.S. market, yet little is known regarding their evolving adoption for prophylaxis of atrial fibrillation (AF)-related stroke. We examined temporal trends in choice of oral anticoagulants (OACs) among incident OAC users with AF and its association with patient demographic and clinical characteristics. METHODS We conducted a serial cross-sectional analysis of medical and pharmacy claims for commercial and Medicare Advantage enrollees in a large, private, U.S. health plan. We identified 112,187 adults with nonvalvular AF starting OACs between October 2010 and March 2017. Multivariable logistic regression was used to examine the associations of patient characteristics with prescription of NOACs versus warfarin. Multinomial logistic regression was used to test the associations of patient characteristics with choice among NOACs. RESULTS The prescription of NOACs has increased dramatically since their introduction in October 2010.
Atrial fibrillation (AF), the most common cardiac arrhythmia, increases the risk of ischemic stroke 5-fold. [1] [2] [3] For decades, anticoagulation with warfarin has been the cornerstone of stroke prevention in AF, but its usefulness is limited by a narrow therapeutic window, need for frequent monitoring, and a restricted diet. 4 Since 2010, several non-vitamin K antagonist oral anticoagulants (NOACs) without these limitations have been approved by the U.S. Food and Drug Administration (FDA) for preventing stroke in patients with nonvalvular AF (dabigatran in October 2010, rivaroxaban in November 2011, apixaban in December 2012, and edoxaban in January 2015). These drugs have been shown to be superior to warfarin in stroke prevention and carry a similar overall bleeding risk with reduction in intracranial hemorrhage but an increase in major gastrointestinal bleeding. [5] [6] [7] [8] Prior studies have examined the uptake of these new drugs and compared their use with warfarin since their market availability in the United States in 2010. Younger age, male sex, white race, fewer comorbidities, lower stroke or bleeding risk, and prescription by a cardiologist have been shown to be associated with higher odds of choosing a NOAC over warfarin. [9] [10] [11] [12] [13] [14] [15] [16] However, most studies focused on dabigatran and rivaroxaban and used data from 2012 and earlier. [12] [13] [14] [15] [16] Although several studies used more recent data, they included a relatively small sample of patients and especially of those with apixaban. [9] [10] [11] For example, one group 9 examined 6893 patients with AF newly prescribed an oral anticoagulant (OAC) between October 2010 and June 2013 in a commercial claims database and identified only 20 new apixaban users. Similarly, other researchers 10 found that among patients with AF treated in a large primary care practice network between 2010 and 2015, only 56 patients used apixaban. In another study of a national registry involving 4670 patients with AF treated with an OAC between February 2013 and January 2016, rivaroxaban was the most frequently used OAC. 11 Moreover, few studies examined patient characteristics associated with prescription patterns among NOACs.
With increased availability of NOACs and ongoing dissemination of information about these drugs in the United States, prescribing patterns and factors driving treatment choice may be evolving. Therefore, we examined (i) temporal trends in incident prescription of warfarin, dabigatran, rivaroxaban, and apixaban from October 2010 through March 2017, (ii) the associations of patient demographic characteristics (e.g., age, sex) and clinical factors (e.g., ischemic stroke risk, prescribing specialty) with prescription of a NOAC versus warfarin, and (iii) the associations between demographic and clinical factors and the choice of NOACs.
Methods

Data Sources
We used data from the OptumLabs Data Warehouse (OLDW), which includes de-identified medical and pharmacy claims for commercial and Medicare Advantage enrollees in a large, private, U.S. health plan. The database contains longitudinal health information on enrollees of all ages and racial/ethnic groups from geographically diverse regions across the country. 17 The claims contain extensive servicelevel data for physician and hospital services as well as information on each prescription filled, such as the drug, the prescriber, and his/her clinical specialty. 17 Our study was exempt from institutional review board approval because it only involved analysis of pre-existing, deidentified data.
Study Participants
The study cohort included patients aged ≥ 18 years with nonvalvular AF who had a new fill of warfarin, dabigatran, rivaroxaban, or apixaban between October 2010 and March 2017. The first fill date for any of these drugs during that period was designated as the index date. Eligibility requirements included continuous enrollment in a medical and pharmacy plan for at least 12 months prior to the index date to ensure completeness of claims information and at least one inpatient or outpatient AF diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 427.31 or ICD-10-CM code I48.0, I48.1, I48.2, or I48.91) 10, [18] [19] [20] within 12 months before the index date. The ICD code performed relatively well with a median positive predictive value of 89% in previous validation studies. 18 Patients with AF who did not have a diagnosis or procedure code indicating valvular heart disease 9, 13 within 12 months preceding the index date were considered as having nonvalvular AF, defined as the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair according to the 2014 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) Guideline. 21 We excluded patients who had an OAC fill within 12 months before the index date, had a diagnosis of deep vein thrombosis or pulmonary embolism within 12 months before the index date, underwent total hip or knee replacement within 6 weeks prior to the index date, or initiated edoxaban during the study period due to a small sample size of only 167 patients.
Baseline Characteristics
Patient demographic and clinical data included age, sex, race/ethnicity, education status, household net worth, region of residence, prescriber specialty, comorbidity, ischemic stroke risk, bleeding risk, and use of antiplatelets or nonsteroidal antiinflammatory drugs (NSAIDs). Providers who prescribed an OAC at the index date were classified as cardiologists, primary care physicians (PCPs), and other providers. To measure the burden of comorbidities, we applied the Quan enhanced ICD-9-CM and ICD-10-CM coding algorithms for Charlson comorbidity index (CCI) to medical claims within 12 months prior to the index date 22 and grouped the score into three groups (0-1, 2-3, and ≥ 4). The Quan coding algorithms have been shown to produce similar estimates of comorbidity prevalence in claims data and may outperform the original Deyo coding algorithms. 22 Ischemic stroke risk was measured using a CHA 2 DS 2 -VASc score, which was calculated by assigning 1 point each for congestive heart failure, hypertension, diabetes mellitus, vascular diseases, age 65-74 years, and female sex and 2 points each for age ≥ 75 years and previous stroke, transient ischemic attack, or thromboembolism. 23 The score ranged from 0 to 9 and was categorized as 0-1, 2-3, and ≥ 4. Bleeding risk was assessed using a modified HAS-BLED score, which was calculated by giving 1 point each for hypertension, abnormal renal function, abnormal liver function, stroke, bleeding history or predisposition, age ≥ 65 years, concomitant use of antiplatelets or NSAIDs, and alcohol abuse. 24, 25 We did not include the labile international normalized ratio (INR) in the score because INR monitoring is not applicable to NOAC therapy. 24, 26 The score ranged from 0 to 8 and was classified as 0-1, 2, and ≥ 3. The comorbidity components of CHA 2 DS 2 -VASc and HAS-BLED were identified within 12 months before the index date using ICD codes based on previously used algorithms. [27] [28] [29] Outcomes
The outcome variables were prescription of a NOAC (dabigatran, rivaroxaban, or apixaban) versus warfarin and choice among the three NOACs at the index date.
Statistical Analysis
We examined baseline characteristics by OAC (warfarin, dabigatran, rivaroxaban, apixaban). Temporal trends in OAC prescriptions were plotted as the proportion of patients starting a specific OAC per quarter for the whole cohort and by selected baseline characteristics.
Multivariable logistic regression was used to examine the associations of patient characteristics with prescription of a NOAC versus warfarin and reported odds ratios (ORs) and 95% confidence intervals (CIs). Because CHA 2 DS 2 -VASc includes patient age, sex, and commodities, some of which were also included in HAS-BLED and CCI, we conducted separate models for these variables to avoid potential multicollinearity. The main model included patient age, sex, race/ethnicity, education, household net worth, region of residence, prescriber specialty, CCI, and comorbidity components of CHA 2 DS 2 -VASc and HAS-BLED that were not already included in CCI. The second model included the CHA 2 DS 2 -VASc score, but excluded patient age, sex, and comorbidities already included in the score. The third model included the HAS-BLED score, but excluded patient age and comorbidities already included in the score. The models were also controlled for a linear time term (calendar quarter) to capture temporal trends in patient characteristics and OAC choice.
Statistical significance was set at p<0.05, and all tests were two-tailed. SAS version 9.4 (SAS Institute Inc, Cary, NC, US) was used for all analyses.
Results
Cohort Description and Baseline Characteristics
The final cohort included 112,187 patients with nonvalvular AF newly prescribed an OAC between October 2010 and March 2017 (Figure 1 NOACs were adopted into clinical practice much more rapidly in patients aged 18-64 years; prescriptions for warfarin were surpassed by dabigatran, rivaroxaban, and apixaban in 2011Q3, 2013Q2, and 2014Q3, respectively (Figure 3) . In contrast, the prescription of dabigatran or rivaroxaban had never overtaken warfarin during the study period among patients aged ≥ 75 years. From 2015Q3, NOACs accounted for over 80% of new OAC prescriptions among patients aged 18-64 years, but had never exceeded 80% of new OAC prescriptions among patients aged ≥ 65 years. Nevertheless, apixaban prescription increased the most rapidly in patients aged ≥ 75 years, reaching 52.4% in 2017Q1 in contrast with less than half among those aged < 75 years.
Temporal Trends by Sex A higher proportion of women (93.9%) than men (90.7%) were prescribed warfarin in 2010Q4 (Figure 4) . However, because NOAC prescriptions increased more rapidly among women than men, by 2017Q1, a lower proportion of women (19.7%) than men (22.2%) were prescribed warfarin. The higher rate of the increasing NOAC prescription in women versus men was attributable to apixaban; the proportion of women treated with apixaban was, on average, 4 percentage points higher than that of men in 2015-2017Q1. In 2017Q1, 53.3% of women were prescribed apixaban compared with 47.4% of men.
Temporal Trends by Ischemic Stroke Risk
The uptake of NOACs was slower among patients with the CHA 2 DS 2 -VASc score ≥ 4; by 2015Q4, warfarin was still the most prescribed OAC in this group (39.8%) ( Figure 5 ). In contrast, warfarin became the second most prescribed OAC in 2014Q1 and 2011Q3 among patients with the CHA 2 DS 2 -VASc score of 2-3 and 0-1, respectively. Nevertheless, among patients with the CHA 2 DS 2 -VASc score ≥ 4, apixaban became the most prescribed OAC from 2016Q1, and accounted for 51. ( Figure 6 ). The prescription of warfarin by cardiologists was overtaken by dabigatran, rivaroxaban, and apixaban in 2011Q3, 2013Q2, and 2014Q2, respectively. Conversely, the prescription of dabigatran or rivaroxaban by PCPs never surpassed warfarin during the study period, but more apixaban than warfarin was prescribed by PCPs in 2016Q2. In 2016-2017Q1, more than 51% of cardiologists prescribed apixaban, while less than 46% of PCPs prescribed the drug.
Factors Associated with Prescription of NOACs versus Warfarin
In the multivariable logistic regression analysis, the factors that were significantly less likely to be associated with a prescription for a NOAC versus warfarin were advanced age; higher CHA 2 DS 2 -VASc, HAS-BLED, or CCI scores; lower education level or household net worth; and prescription by a PCP (vs cardiologist) in all three periods (Table 2) . For example, compared with patients ages 18-64 years, patients aged ≥ 75 years were 56% and 51% less likely to initiate a NOAC versus warfarin in 2010Q4-2012 and 2015-2017Q1, respectively. Compared with cardiologists, PCPs were 64% and 59% less likely to prescribe a NOAC versus warfarin for incident OAC users in 2010Q4-2012 and 2015-2017Q1, respectively. The association between sex and prescription of a NOAC versus warfarin changed over time. Males and females had a similar likelihood of filling a NOAC versus warfarin in 2010Q4-2012, whereas women had higher odds of NOAC prescriptions in 2013-2014 (OR = 1.06, 95% CI = 1.01-1.11) and 2015-2017Q1 (OR = 1.19, 95% CI = 1.14-1.25).
Factors Associated with Choice among NOACs
In the multinomial logistic regression analysis, apixaban was generally preferred over dabigatran or rivaroxaban as a new prescription for elderly, women, and patients with higher CHA 2 DS 2 -VASc, HAS-BLED, or CCI scores in both periods (Table 3) The results came from models that adjusted for all these variables and comorbidity components of CHA 2 DS 2 -VASc and HAS-BLED that were not already included in Charlson comorbidity index. The results came from models that adjusted for race/ethnicity, education, household net worth, region of residence, prescriber specialty, calendar quarter, and comorbidity components of Charlson comorbidity index and HAS-BLED that were not already included in CHA 2 DS 2 -VASc. The results came from models that adjusted for sex, race/ethnicity, education, household net worth, region of residence, prescriber specialty, calendar quarter, and comorbidity components of Charlson comorbidity index and CHA 2 DS 2 -VASc that were not already included in HAS-BLED. The results came from models that adjusted for all these variables and comorbidity components of CHA 2 DS 2 -VASc and HAS-BLED that were not already included in Charlson comorbidity index. The results came from models that adjusted for race/ethnicity, education, household net worth, region of residence, prescriber specialty, calendar quarter, and comorbidity components of Charlson comorbidity index and HAS-BLED that were not already included in CHA 2 DS 2 -VASc.
c
The results came from models that adjusted for sex, race/ethnicity, education, household net worth, region of residence, prescriber specialty, calendar quarter, and comorbidity components of Charlson comorbidity index and CHA 2 DS 2 -VASc that were not already included in HAS-BLED.
Discussion
In this large retrospective study of patients with nonvalvular AF starting OAC therapy between October 2010 and March 2017, we found that the proportion of incident OAC users receiving NOAC prescriptions increased dramatically immediately following their introduction to the market, accounting for approximately 80% of incident OAC users in 2017Q1. Apixaban has become the most frequently prescribed OAC since 2015Q3 and accounted for half of the incident OAC prescriptions in 2017Q1. Compared with warfarin, NOACs were less likely to be prescribed to elderly, patients with higher stroke or bleeding risk, patients with more comorbidities, and those with lower education level or household net worth but more likely to be prescribed by a cardiologist. Among incident NOAC users, older age, female sex, higher stroke or bleeding risk, and more comorbidities were associated with higher odds of apixaban prescription.
Our finding of a substantial increase in incident apixaban prescription over time is consistent with studies from Denmark, 30 Norway, 31 and Sweden 32 that reported an increasing initiation of apixaban, which became the most used OAC for AF in 2015. Although the European Society of Cardiology guidelines recommend the use of a NOAC over warfarin 33, 34 while the AHA/ACC/HRS guideline offers no such preference, 21 physicians in both the United States and Europe tended to prescribe more NOACs than warfarin over time. In addition, we found that the prescription of apixaban rose with increasing age, in concordance with a recently published review that recommended apixaban as first choice of OAC therapy for patients with AF older than 75 years. 35 It is possible that the prescribing pattern of apixaban may be influenced by a perception of favorable safety profiles of the drug for patients with AF regardless of age. 28, 36, 37 For example, it was reported that apixaban was associated with a lower risk of stroke or systemic embolism, major bleeding, and death compared with warfarin in patients with AF of all ages, with an even greater benefit with advanced age. 36 The sharp reduction in dabigatran prescription 1 year after its FDA approval was likely due to the introduction of rivaroxaban and apixaban. Nevertheless, it may be more likely to reflect physician reaction to early case reports of myocardial infarction and fatal bleeding, [38] [39] [40] FDA warnings of significant risk of bleeding and gastrointestinal side effects, concerns over the validity of the data and outcomes from the original clinical trial used for FDA approval, and litigations against the drug.
41, 42 Although a recent study found that relative effectiveness and safety with dabigatran versus warfarin was in line with that reported in the trial, 43 how this finding affects dabigatran prescription is not yet known. Moreover, about 80% of dabigatran is eliminated by the kidney, higher than 27% and 36% renal elimination for apixaban and rivaroxaban, respectively. 44 Therefore, physicians may be more reluctant to prescribe dabigatran to patients with impaired renal function, which often occurs in patients who are elderly or have comorbidities. In addition, although idarucizumab, a reversal agent for dabigatran, was approved by the FDA in October 2015, 45 our results showed that dabigatran prescription did not increase afterwards. This is contrary to the assumption that a NOAC would be more commonly prescribed if there was an available antidote. 11-13, 46, 47 We found that the association between female sex and prescription of a NOAC versus warfarin changed over time, from no significant association in 2010Q4-2012 to a positive association in 2013-2017Q1. This may be related to a slightly higher rate of increasing prescription of apixaban over time among women than men. A prior U.S. study using registry data in 2010-2014 also found that NOAC use increased at a slightly higher rate in women relative to men. 48 According to a meta-analysis, compared with men, women treated with a NOAC had a lower risk of major bleeding while those treated with warfarin had a higher risk of stroke and systemic embolism, suggesting an increased net clinical benefit of NOACs compared with warfarin in preventing stroke among women with AF. 49 Our finding that cardiologists were more likely to prescribe a NOAC versus warfarin is consistent with prior studies in the United States 11, 12, 16 This finding is not surprising given that cardiologists are specialists most commonly involved in care for patients with AF. They are possibly more familiar with the literature about NOAC use and have more experience in prescribing a NOAC and thus may have a higher level of comfort with NOAC prescriptions. 50 What is unique from our findings is that the strength of the positive association between prescriber specialty (PCPs vs cardiologists) and the prescription of rivaroxaban or dabigatran versus apixaban decreased or became insignificant over time.
Our study has several limitations. First, our analysis of OAC prescriptions among commercial and Medicare Advantage beneficiaries may not represent treatment decisions for all patients with AF in the United States. However, our cohort consisted of a large diverse patient population across various geographic regions, and thus our findings of the associations between patient characteristics and OAC choice may be generalizable to the insured patients in AF in the country. Second, although we included a variety of relevant confounders in our analysis, we cannot rule out the possibility of unobserved factors, such as formulary restrictions, and physician and patient preferences, which may be associated with the selection of an OAC. Third, the claims we used may have coding errors that led to misclassifications of patients with nonvalvular AF. However, the ICD codes for nonvalvular AF were commonly used in studies using claims and registry data. 10, [18] [19] [20] Fourth, although we were able to identify OAC prescriptions from the claims, we do not know whether the patients actually took these drugs. Fifth, pharmacy claims included data on prescriptions filled, and thus represent a subset of prescriptions written by physicians. The proportion of prescriptions written that were not filled (i.e., the rate of primary nonadherence) could be higher in NOACs than warfarin due to higher copays for NOACs. Therefore, the study may underestimate the proportion of NOACs being prescribed. Finally, because claims do not include information on the use of over-the-counter drugs, the proportion of patients prescribed antiplatelets or NSAIDs may be underestimated. Nevertheless, the underestimation is expected to be nondifferential across different OAC groups.
In conclusion, NOAC prescriptions have increased substantially in patients with nonvalvular AF who are starting OAC therapy. Clinical practice tended to respond rapidly to evidence of effectiveness and harm associated with apixaban and dabigatran. Apixaban became the most prescribed OAC eventually and was mainly prescribed to elderly, women, patients with higher stroke or bleeding risk, and those with more comorbidities. The association of certain patient characteristics, such as sex and prescriber specialty, with OAC choice changed over time. This finding together with increased availability of NOACs underscores the need for careful, ongoing surveillance of the use of OACs in different patient populations in clinical practice and for longitudinal effectiveness and safety analyses of these drugs.
